Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Abstract Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD...

Full description

Bibliographic Details
Main Authors: Jillian R. Gunther, Chelsea C. Pinnix, Gordon R. Glober, Kaitlin M. Christopherson, Penny Fang, Hun Ju Lee, Sairah Ahmed, Raphael E. Steiner, Ranjit Nair, Paolo Strati, Sattva S. Neelapu, Loretta J. Nastoupil, Bouthaina S. Dabaja
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:eJHaem
Subjects:
chemotherapy
Hodgkins lymphoma
radiotherapy
Online Access:https://doi.org/10.1002/jha2.1

Internet

https://doi.org/10.1002/jha2.1

Similar Items